Rezolute Medical Affairs

We look forward to:
• Sharing updates on therapy innovations
• Providing educational resources
• Fostering meaningful connections within the HI community
Scan the QR code below to subscribe to our program & monthly e-newsletter, 𝘛𝘩𝘦 𝘙𝘦𝘻𝘰𝘭𝘶𝘵𝘪𝘰𝘯 𝘙𝘦𝘱𝘰𝘳𝘵
Click here to learn more: bit.ly/4iadvda
#MedSky

As patients navigate life with #hyperinsulinism, #Rezolute Patient Affairs team is committed to walking alongside them every step of the way. That’s why we are excited to launch 𝘛𝘩𝘦 𝘙𝘦𝘻𝘰𝘭𝘶𝘵𝘪𝘰𝘯, a new initiative dedicated to supporting those impacted by hypoglycemia related to hyperinsulinism

We were honored to attend the UKI NETS Annual Conference yesterday and connect with leading experts and people impacted by #insulinomas, a rare type of neuroendocrine tumor.
At Rezolute, we’re committed to advancing care options for the #hyperinsulinism
#MedSky #EndoSky #OncSky #raredisease

November is #NationalFamilyCaregiversMonth, a time to honor and celebrate the incredible #caregivers who provide invaluable support to the #hyperinsulinism community.

Hear more from caregivers here: bit.ly/46IK51G

#Rezolute #congenitalHI #tumorhyperinsulinism #raredisease #MedSky #EndoSky #PedSky

Today is #WorldPancreaticCancerDay, and we're shining a light on #insulinomas - a rare type of tumor that usually forms from the insulin-secreting cells in the pancreas, resulting in hypoglycemia.

Explore how #Rezolute is working to shape the future of #hyperinsulinism: bit.ly/46IK51G
#MedSky

#Rezolute was proud to be a Diamond Sponsor of Congenital Hyperinsulinism International’s Sugar Soirée on Saturday, an annual fundraiser that supports families impacted by #congenitalHI and raises awareness.
Learn more about our Phase 3 trial in congenital HI here: bit.ly/47K5Oa3
#EndoSky #PedSky

#Rezolute is proud to support Neuroendocrine Cancer Awareness Day! Neuroendocrine tumors (NETs) can have a profound impact on patients’ lives, so join us in raising awareness and supporting those affected by NET cancers.
#LetsTalkAboutNETs #NETCancerDay #tumorhyperinsulinism #OncSky #EndoSky #MedSky

To learn more about our sunRIZE Phase 3 preliminary demographic and baseline clinical characteristics, please check out our poster on our website: rezolutebio.com/wp-content/u... #SPES2025
#RZLT #CongenitalHI #raredisease #hyperinsulinism #ersodetug #PedSky #EndoSky #MedSky

Our team was proud to attend the Southern Ped Endo Society Annual Meeting at UAB in Birmingham this past weekend, presenting an encore poster presentation of the preliminary demographic and baseline clinical characteristics from our Phase 3 #sunRIZE trial. #RZLT #SPES2025 #RZLTInAction #CongenitalHI

Stay connected through The Rezolution—our new initiative for patients & caregivers featuring updates on therapies, advocacy, events & resources. Visit #RZLT For Patients page to learn more, meet our team & sign up for The Rezolution Report-our monthly newsletter bit.ly/46IK51G #congenitalHI #EndoSky

💙 #Rezolute was honored to support the #CHI Family Conference at @childrensphila.bsky.social this past weekend! Grateful to CHI, the physicians, and—most importantly—the patients & families who connected with the team and shared their #congenitalhyperinsulinism stories.
#PedSky #RZLTInAction

What a weekend for #Rezolute Medical Affairs! 🌍 Our team proudly represented at #ASPED2025 (Dubai), #SCOPE (Long Beach), and #AAP2025 (Denver)—sharing insights on congenital hyperinsulinism and ersodetug (RZ358). Grateful to all who engaged with us! #RZLT #ersodetug #EndoSky #RZLTMedAffairsInAction

Excited to be at ASPED 2025 in Dubai to increase awareness of #Hyperinsulinism

This is an incredible outcome, representative of the Agency's recognition of ersodetug as a potential universal treatment for multiple forms of HI, and the high unmet need in this patient population. #EndoSky #MedSky #OncSky #RareDisease #Hyperinsulinism #TumorHI

Today we announced alignment with FDA on a streamlined design for the ongoing Phase 3 trial of ersodetug in patients with tumor hyperinsulinism (HI). Learn more: bit.ly/4mM7qVV

#MedSky #EndoSky #OncSky #TumorHI #Hyperinsulinism #RareDisease #DrugDevelopment

Proud to take part in this past weekend's 16th Annual Kongenitaler Hyperinsulinismus, e.V. meeting in Berlin, Germany. The Association continues to empower families facing #congenitalHI with education and support across every stage of life. #RareDisease #Hyperinsulinism #MedSky #EndoSky #PedSky

We applaud Congenital Hyperinsulinism International, the authors, and—most importantly—the patients and families—for their groundbreaking, innovative study on the real-world experience of diazoxide in congenital hyperinsulinism. #MedSky #EndoSky #PedSky #CongenitalHI #Hyperinsulinism

It was a privilege to connect with patients, caregivers, clinicians, and researchers who are united in advancing care for those affected by #cHI. We appreciate the ongoing collaboration and making a lasting impact for all those living with #hyperinsulinism!
#CongenitalHI #MedSky #EndoSky #RZLT

🌍💙 Grateful to Connect at the UK Congenital HI Family Conference
A heartfelt thank you to the organizers and families who made this past weekend’s @chcharityuk.bsky.social #Hyperinsulinism Charity Family Conference in the UK such an inspiring and meaningful experience.

Meeting Sarah Dearman at the Children’s Hyperinsulinism Charity conference and learning about the charity’s work was inspiring. It was great to connect face to face with Davelyn Hood from Rezolute. Ersodetug offers real hope for better care, and I am excited about future collaboration #insulinoma

📈ICYMI we presented Preliminary Patient Demographics And Baseline Characteristics from Phase 3 Study #sunRIZE of Ersodetug for Hypoglycemia due to #CongenitalHI at #ENDO2025
📎 View the full poster here: bit.ly/416Pdt5
🙏Thank you to all who stopped by and engaged with us
#EndoSky #MedSky #Ph3 #RZLT

Proud to present "Preliminary Patient Demographics and Baseline Characteristics From a Phase 3 Study (sunRIZE) of Ersodetug for Hypoglycemia Due to Congenital Hyperinsulinism: Trial in Progress" today at #ENDO2025. View the full poster here: bit.ly/44x4GF6 #EndoSky #MedSky #CongenitalHi #RZLT

If you’re at #ENDO2025 join Rezolute's team today 4:30-6:30pm at the #HypoglycemiaHappyHour on top of Moscone Center North. Learn about our #InsulinReceptorModulatingAntibody ersodetug, and the growing body of evidence to treat all forms of #hyperinsulinism #PostBariatricHI #TumorHI #CongenitalHI

If attending the event, swing by to say hello on 7/14 at 12pm PT to learn more about this patient population and our progress in the space: bit.ly/3TqU1pf #ENDO2025 #ENDO #MedSky #PedSky #EndoSky #hypoglycemia #hyperinsulinism #congenitalHI #RZLT #Biotech

We're thrilled to present “Preliminary Patient Demographics And Baseline Characteristics From A Phase 3 Study (sunRIZE) Of Ersodetug For Hypoglycemia Due To Congenital Hyperinsulinism: Trial In Progress" at #ENDO2025 in San Francisco! #ENDO #MedSky #PedSky #CongenitalHI #RZLT #biotech

Dive into the latest issue to reacquaint yourself with our Phase 2b (RIZE) study on congenital hyperinsulinism and see the science behind the visuals! (4/4) www.sciencedirect.com/science/arti...
#MedSky #PedSky #CongenitalHI #Ersodetug #Hyperinsulinism #Hypoglycemia #RareDisease

Why is this illustration powerful
•Shares insights into ersodetug’s MOA
•Provides visual context for the powerful science described in the RIZE Study results in this issue of Med
•Highlights ersodetug’s effects downstream of the pancreas making it a potential therapy for all forms of hyperinsulinism

Ersodetug is a fully human monoclonal antibody (IgG2) that binds allosterically and reversibly to the insulin receptor (INSR) to attenuate excess signaling, thus improving hypoglycemia. (2/4)

🎨 Cover Art Reveal: Unpacking the Science 🧬
Checkout Med’s journal cover this month, which illustrates Ersodetug as an insulin receptor modulating antibody (1/4)
#Med #Ersodetug #MOA #RareDisease #Hyperinsulinism #CongenitalHI #Hypoglycemia #ScientificArt #VisualStorytelling #MedSky

💙 This dedicated German advocacy organization has been a tireless voice for those affected by congenital hyperinsulinism (HI) through their EDUCATION, VISIBILITY AND COHESION efforts. (3/3) #MedSky #PedSky #RareDisease #CongenitalHI #Hyperinsulinism #Hypoglycemia